Regeneron (REGN) Earns "Outperform" Rating from Cowen

Cornelia Mascio
Mag 16, 2018

Finally, UBS Asset Management Americas Inc. raised its stake in shares of Regeneron by 93.5% in the fourth quarter.

Kbc Group Nv stated it has 7,085 shares or 0.02% of all its holdings.

NASDAQ:REGN opened at $309.54 on Tuesday. Rafferty Asset Mgmt Lc invested in 3,787 shares. It also reduced its holding in Weibo (NASDAQ:WB) by 6,800 shares in the quarter, leaving it with 239,970 shares, and cut its stake in Paypal Holdings. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since May 13, 2017 and is downtrending. Allsquare Wealth Mngmt Limited Liability Com invested in 0.03% or 105 shares.

Regeneron (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 3rd.

Trend Direction of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Ww owns 4.81 million shares. Alpha Windward Ltd Limited Liability Company holds 389 shares. Cwm Ltd invested in 0% or 18 shares.

Since February 9, 2018, it had 0 insider purchases, and 4 sales for $7.43 million activity. (NASDAQ:REGN) for 20,495 shares.

In other news, Director George L. Sing sold 7,000 shares of the firm's stock in a transaction on Wednesday, May 9th. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company's shares. The brokerage now has a buy rating on the biopharmaceutical company's stock.

Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on August, 2. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $1.05. The stock increased 0.28% or $0.845 during the last trading session, reaching $307.785. It has underperformed by 25.74% the S&P500. About 331,639 shares traded. (NASDAQ:REGN) on Wednesday, January 24 with "Neutral" rating. They analyze the different factor and after that analysis they issue rating regarding stock whether it is time to buy the stock or sell the stock or even hold the stock based on analyzing factors. During the same quarter in the previous year, the company earned $2.92 EPS. research analysts forecast that Regeneron will post 17.2 earnings per share for the current year. (NASDAQ:REGN) has "Hold" rating given on Thursday, February 8 by BMO Capital Markets. Therefore 57% are positive. Finally, Jefferies Group reissued a hold rating and issued a $380.00 price target on shares of Regeneron in a research note on Thursday, February 8th.

Dominion Energy, Inc. (NYSE:D), maintained return on investment for the last twelve months at 3.30, higher than what Reuters data shows regarding industry's average. Regeneron had a return on equity of 28.48% and a net margin of 20.41%. The stock has "Sell" rating by Chardan Capital Markets on Monday, November 7. The company was downgraded on Monday, April 9 by Raymond James. Leerink Swann has "Outperform" rating and $502 target. Credit Suisse maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: "Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside" published on May 03, 2018 as well as's news article titled: "Why Regeneron Has 30 Percent Upside" with publication date: May 07, 2018.

More important recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: which released: "Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC" on May 15, 2018, also with their article: "Better Buy: Amgen Inc. vs. Biogen Inc." published on May 15, 2018, published: "Regeneron: Initiating At These Levels" on May 10, 2018. (NASDAQ:REGN) on Tuesday, April 17 with "Buy" rating.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The Company's products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes. It has a 29.68 P/E ratio. The company has market cap of $6.78 million. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE